📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.

Atrys Health SA

Common Name
Atrys Health
Country
Spain
Sector
Healthcare
Industry
Biotechnology
Employees
2,016
Ticker
ATRY
Exchange
BOLSA DE MADRID
Description
Atrys Health S.A. is a prominent healthcare company specializing in medical and cancer diagnostics, radiotherapy services, and telemedicine. It plays a critical role in advancing the medical field by ...

Atrys Health's GHG Emissions Data Preview

In 2024, Atrys Health completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Atrys Health has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 2
Market-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Location-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Data
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=ATRY&reporting_period=2024"

Verified Sources Behind Atrys Health’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Atrys Health’s data sources below and access millions more through our Disclosure Search.

a. Atrys Health's Financial Report 2024
a. Atrys Health's Financial Report 2024

Insights into Atrys Health's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions ofAtrys Health amounted to1,029.9metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Atrys Healthdecreased by 3.48%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Atrys Health's Scope 1 Emissions Over Time

2022202320240200400600800tCO2e-3%-5%
  • Total Scope 1
  • Year-over-Year Change

What are Atrys Health's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Atrys Health were 592 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a

Has Atrys Health reduced its Scope 1 emissions over time?

Since 2022, Atrys Health's Scope 1 emissions have decreased by 7.21%, reflecting a declining long-term trend in Scope 1 emissions over time.a

Compared to the previous year(2023), Atrys Health's Scope 1 emissions decreased by 4.67%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Atrys Health's Scope 2 emissions?

In 2024, Atrys Health reported Scope 2 greenhouse gas (GHG) emissions of 438 tCOâ‚‚e using the market-based method and 437.9 tCOâ‚‚e using the location-based method.a

What methodology does Atrys Health use for Scope 2 reporting?

In 2024, Atrys Health reported its Scope 2 emissions using the market-based method and using the location-based method.a

Atrys Health's Scope 2 Emissions Over Time

2022202320240150300450600tCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Atrys Health's Value Chain Emissions

In 2024, Atrys Health reported 6,429 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Atrys Health includes a breakdown across 1of the 15 Scope 3 categories defined by the GHG Protocol,up from 0 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina

Atrys Health's Scope 3 Emissions Over Time

202402 k4 k6 k8 ktCO2e
  • Total Scope 3
  • Year-over-Year Change

What are Atrys Health's Scope 3 emissions?

In 2024, Atrys Health reported total Scope 3 emissions of 6,429 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a

What categories of Scope 3 emissions does Atrys Health disclose?

In 2024, Atrys Health reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol.a

The limited disclosure restricts visibility into specific emission sources across the company's value chain.

What are the main sources of Atrys Health's Scope 3 emissions?

In 2024, the largest contributors to Atrys Health's Scope 3 emissions were:a

  • Other/Unspecified Sources: 253 tCOâ‚‚e(100%)

Atrys Health's Scope 3 Emissions by Categories

Other/UnspecifiedSources(100.0%)

Insights into Atrys Health’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Atrys Health reported Scope 1 greenhouse gas (GHG) emissions of 592 tCOâ‚‚e and total revenues of USD 221 millions. This translates into an emissions intensity of 2.67 tCOâ‚‚e per millions USD.a

Atrys Health's Scope 1 Emissions Intensity Compared to Peers

0.52050010,000500,000Scope 1 Emissions (tCO2e)5505005,000100,000Revenues (Millions of USD)BALCSICInnoCare PharmaYear: 2023Scope 1: 20 tCO2eRevenue: $M 104Scope 1 Intensity: 0.19 tCO2e/$MPharma MarYear: 2023Scope 1: 1,233 tCO2eRevenue: $M 175Scope 1 Intensity: 7.04 tCO2e/$MBBBlue Jet HealthcareYear: 2025Scope 1: 23,877 tCO2eRevenue: $M 120Scope 1 Intensity: 198.82 tCO2e/$MBB BiotechYear: 2024Scope 1: 12 tCO2eRevenue: $M 91Scope 1 Intensity: 0.13 tCO2e/$MEverest MedicinesYear: 2024Scope 1: 1 tCO2eRevenue: $M 106Scope 1 Intensity: 0.00 tCO2e/$MFrontage HoldingsYear: 2023Scope 1: 2,883 tCO2eRevenue: $M 2,027Scope 1 Intensity: 1.42 tCO2e/$MPeptiDreamYear: 2023Scope 1: 3,156 tCO2eRevenue: $M 203Scope 1 Intensity: 15.55 tCO2e/$MAAAurisco PharmaceuticalYear: 2024Scope 1: 2,731 tCO2eRevenue: $M 202Scope 1 Intensity: 13.51 tCO2e/$MLLLigaChem BiosciencesYear: 2023Scope 1: 308 tCO2eRevenue: $M 27Scope 1 Intensity: 11.53 tCO2e/$MCCConcord BiotechYear: 2025Scope 1: 13 tCO2eRevenue: $M 138Scope 1 Intensity: 0.09 tCO2e/$MSSSichuan Kelun-Biotech BiopharmaceuticalYear: 2023Scope 1: 6,335 tCO2eRevenue: $M 237Scope 1 Intensity: 26.78 tCO2e/$MBiotestYear: 2020Scope 1: 18,574 tCO2eRevenue: $M 384Scope 1 Intensity: 48.41 tCO2e/$MAscendis PharmaYear: 2024Scope 1: 62 tCO2eRevenue: $M 443Scope 1 Intensity: 0.14 tCO2e/$MGubraYear: 2024Scope 1: 8 tCO2eRevenue: $M 37Scope 1 Intensity: 0.22 tCO2e/$MCSLYear: 2025Scope 1: 135,000 tCO2eRevenue: $M 23,347Scope 1 Intensity: 5.78 tCO2e/$MVIVA Biotech HoldingsYear: 2022Scope 1: 1,404 tCO2eRevenue: $M 373Scope 1 Intensity: 3.76 tCO2e/$MBiontechYear: 2024Scope 1: 2,405 tCO2eRevenue: $M 3,341Scope 1 Intensity: 0.72 tCO2e/$MCamurusYear: 2024Scope 1: 116 tCO2eRevenue: $M 169Scope 1 Intensity: 0.68 tCO2e/$MCytokineticsYear: 2024Scope 1: 242 tCO2eRevenue: $M 18Scope 1 Intensity: 13.10 tCO2e/$MIIInventivaYear: 2024Scope 1: 554 tCO2eRevenue: $M 10Scope 1 Intensity: 57.88 tCO2e/$MAlnylam PharmaceuticalsYear: 2024Scope 1: 3,832 tCO2eRevenue: $M 2,248Scope 1 Intensity: 1.70 tCO2e/$MBeOne MedicinesYear: 2024Scope 1: 3,547 tCO2eRevenue: $M 27,369Scope 1 Intensity: 0.13 tCO2e/$MPharmaron BeijingYear: 2024Scope 1: 34,268 tCO2eRevenue: $M 1,682Scope 1 Intensity: 20.37 tCO2e/$MCCCatalyst PharmaceuticalsYear: 2024Scope 1: 4 tCO2eRevenue: $M 493Scope 1 Intensity: 0.01 tCO2e/$MAtrys HealthYear: 2024Scope 1: 592 tCO2eRevenue: $M 221Scope 1 Intensity: 2.67 tCO2e/$M

How does Atrys Health's GHG emissions intensity compare to its peers?

In 2024, Atrys Health reported a Scope 1 emissions intensity of 2.67 tCOâ‚‚e per millions USD. Compared to the peer group median of 2.73, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Atrys Health rank on GHG emissions intensity within its industry?

In 2024, Atrys Health ranked 13 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a

Atrys Health is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Atrys Health's Total Carbon Footprint

In 2024, Atrys Health reported a total carbon footprint of 7,458.9 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 599.05% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a

The largest contributor to Atrys Health's total carbon footprint was Scope 3 emissions, accounting for 86.19% of the company's total carbon footprint, followed by Scope 1 emissions at 7.94%.a

Want Full Access to Atrys Health's GHG Emissions Dataset?
Sign Up